Support for you and appropriate patients with overt HE
The resources below include information that may help when prescribing XIFAXAN, insurance requirements, and videos about OHE. You’ll also find materials to share with appropriate patients with OHE. These resources may help you get appropriate patients on XIFAXAN and help them reach your goals for OHE management.
AASLD/EASL 2014 Guideline Flashcard
Quickly review some of the recommendations for adult patients with overt HE.
Considerations for PAs Handout
Provides directions for submitting a PA for XIFAXAN when needed.
Sample Letter of Medical Necessity
A standard form for a patient‐specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.
Tier Exception Request
A Tier Exception request to reduce the cost-share of a medication. Follows submission of a PA or Utilization Management request.
OHE = overt hepatic encephalopathy
AASLD = American Association for the Study of Liver Diseases
EASL = European Association for the Study of the Liver
PA = prior authorization
An important recommendation from the AASLD Guidelines
Watch Dr. Jesudian discuss some of the AASLD Guidelines for managing overt HE with XIFAXAN.
Align with the AASLD Guidelines for patients at risk of overt HE recurrence
Listen to Dr. Poordad explain the thinking behind the treatment protocol for reducing the risk of recurring episodes of overt HE.
Efficacy of XIFAXAN for OHE
Watch Dr. Poordad describe the Phase 3 clinical trial that assessed the efficacy of XIFAXAN in reducing the risk of recurrence for overt HE and HE-related hospitalizations.
HE is a problem hiding in plain sight
See Dr. Flamm explain the reasons for screening patients with cirrhosis for hepatic encephalopathy.
Recognizing patients at risk for HE
View Dr. Flamm speaking about the importance of recognizing the symptoms of HE on a wide spectrum of neurological and psychiatric manifestations.
For patients with cirrhosis/chronic liver disease, screen early, before hospitalization
Hear Dr. Flamm describe in detail the symptoms of overt HE, from insomnia to full-fledged coma.
Wrestling the Monster
Study the face of HE in 4 patients and their caregivers as they describe the toll HE takes on them and their families.
HE = hepatic encephalopathy
XIFAXAN HE Living Kit Flashcard
A brief overview about managing OHE with XIFAXAN, including dosing and savings program details.
HE Symptom Checklist
A handy tool to help patients and caregivers recognize the mental and physical symptoms of HE.
Low-income Subsidy Brochure
Learn about Extra Help/LIS program benefits. Identify the two ways patients can receive Extra Help/LIS benefits. Discover how you can help patients apply for Extra Help/LIS benefits.
HE = hepatic encephalopathy
LIS = Low-income subsidy
*Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.
Time to Take Action
Take on this interactive challenge and determine what you would do for these patients.
Get information regarding XIFAXAN
Speak with a XIFAXAN representative
INDICATIONS
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
IMPORTANT SAFETY INFORMATION
- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
- Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.